Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009

Menopause

Volumn 18, Issue 4, 2011, Pages 385-392

  Tsai, Sandra A ^a   Stefanick, Marcia L ^a   Stafford, Randall S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Menopausal hormone therapy; National Disease and Therapeutic Index; Physician practice patterns

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN;

AGE DISTRIBUTION; ARTICLE; CONTINUING EDUCATION; GYNECOLOGY; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; MEDICAL PRACTICE; MENOPAUSE; PHYSICIAN; PRACTICE GUIDELINE; TREND STUDY; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DATA COLLECTION; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; GYNECOLOGY; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MENOPAUSE; MIDDLE AGED; OBSTETRICS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PRACTICE GUIDELINES AS TOPIC; PROGESTINS; UNITED STATES; YOUNG ADULT;

EID: 79955032409     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181f43404     Document Type: Article

References (43)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
2. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53. (Pubitemid 38040534)
3. Labeling guidance for noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptomsV prescribing information for health care providers and patient labeling. 2005. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/UCM135336. Accessed July 20, 2010.
4. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118:64-73.
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712. (Pubitemid 38489892)
6. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365. (Pubitemid 43244325)
7. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477. (Pubitemid 46556472)
8. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
9. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):S1-S66.
10. Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194. (Pubitemid 46752441)
11. Rees M, Stevenson J. Primary prevention of coronary heart disease in women. Menopause Int 2008;14:40-45.
12. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
13. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289:3243-3253. (Pubitemid 37430077)
14. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med 2007;356: 1670-1674. (Pubitemid 46631679)
15. Krieger N. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol 2008;37: 627-637. (Pubitemid 351804018)
16. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24: e49-e50.
17. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662. (Pubitemid 37430136)
18. IMS Health Incorporated. National Disease and Therapeutic Index, January 2000-December 2009. IMS Health, Plymouth Meeting PA, 2010.
19. National Disease and Therapeutic Index Web site. Available at: https://web01.imshealth.com/ndti/Demo/NDTIdemo.html. Accessed July 20, 2010.
20. 2007 NDTI precision table: diagnosis visits (estimated sampling error) two-staged stratified cluster methodology. Dataview Software. Plymouth Meeting, PA: IMS Health Incorporated, 2007.
21. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61. (Pubitemid 36044404)
22. Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A. A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. In: Proceedings of the Section on Survey Research Methods American Statistical Association. Alexandria, VA; 2000:840-845.
23. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050. (Pubitemid 40458772)
24. Hing E, Brett KM. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006;108:33-40. (Pubitemid 44336842)
25. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-188.
26. Du Y, Doren M, Melchert HU, Scheidt-Nave C, Knopf H. Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. BMC Womens Health 2007;7:19.
27. Morabia A, Costanza MC. Recent reversal of trends in hormone therapy use in a European population. Menopause 2006;13:111-115.
28. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360:573-587.
29. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44. (Pubitemid 43192860)
30. Manson JE, Bassuk SS, Harman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13:139-147.
31. Hormone replacement therapy for the prevention of chronic conditions in postmenopausal women. 2005. Available at: http://www.ahrq.gov/clinic/uspstf/ uspspmho.htm#related. Accessed July 20, 2010.
32. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-182.
33. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:571-576. (Pubitemid 38326155)
34. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007;56:231-248. (Pubitemid 46241755)
35. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-983. (Pubitemid 26340752)
36. Appt SE, Clarkson TB, Lees CJ, Anthony MS. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas 2006;55:187-194. (Pubitemid 44307489)
37. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 2007;57:81-84. (Pubitemid 46602903)
38. Modena MG, Sismondi P, Mueck AO, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005;52:1-10. (Pubitemid 41242736)
39. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17A-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-779. (Pubitemid 47508739)
40. Haines C, Yu SL, Hiemeyer F, Schaefers M. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial. Climacteric 2009;12:419-426.
41. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005;11:909s-917s. (Pubitemid 40111105)
42. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118:74-78.
43. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684. (Pubitemid 37430138)